Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, provides an overview of biomarkers in prostate cancer.
Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, provides an overview of biomarkers in prostate cancer.
“The field of biomarkers in prostate cancer is exploding exponentially, and it has been for some time now,” Shore says. “The challenge is that most of the biomarkers that are commercially available are not reimbursed and, some might argue, are truly not yet ready for primetime.”
Novel Drug Granted FDA Fast Track in Rare Prostate Cancer Subset
February 13th 2024The Food and Drug Administration has granted a Fast Track designation to the novel immune activator drug BXCL701 in combination with a checkpoint inhibitor for patients with metastatic small cell neuroendocrine prostate cancer (SCNC).
Read More